Most Read Articles
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
05 Oct 2019
The combination of sofosbuvir and velpatasvir is safe and effective for the treatment of hepatitis C virus (HCV) in patients with end-stage renal disease (ESRD) undergoing haemodialysis, a study has shown.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Glecaprevir–pibrentasvir regimen effective against genotype 2 HCV in haemodialysis patients

29 Jul 2019

An 8- or 12-week regimen of glecaprevir plus pibrentasvir (G/P) appears to be safe and effective in the treatment of genotype 2 hepatitis C virus (HCV) infection in patients undergoing haemodialysis, as reported in a recent Japanese cohort study.

Researchers followed a total of 27 patients who initiated G/P regimen. Thirteen nonliver cirrhosis (LC) and direct-acting antivirals (DAAs)-naïve patients received the 8-week regimen, while 14 patients with LC (n=13) or history of DAA failure (n=1) received the 12-week regimen.

All but one patient (96.3 percent) achieved sustained virological response at 12 weeks following treatment completion (SVR12). There were two cases of treatment withdrawal: one was at week 11 due to cerebral infarction (which was resolved by conservative management) and the other was at week 2 due to exacerbation of pruritis. The patient who discontinued G/P at week 2 belonged to the 12-week regimen arm and could not achieve SVR12.

Adverse events occurred in 51.9 percent (14/27) of the population, with the most common being pruritus (29.6 percent; 8/27). None of the patients experienced lethal adverse events.

Glecaprevir is a novel HCV NS5A inhibitor, while pibrentasvir is an HCV protease inhibitor. Notably, these drugs could initially reduce the treatment duration for HCV-infected patients without liver cirrhosis. The efficacy of the G/P regimen has also been demonstrated in a previous trial involving patients with severe renal dysfunction, but the treatment duration was standardized to 12 weeks.  [J Gastroenterol 2018;53:557-565; Hepatology 2018;68:1298-1307; N Engl J Med 2017;377:1448-1555]

Therefore, the present data show that a shorter treatment duration with G/P, similar to that of patients without severe renal dysfunction, is highly effective for haemodialysis patients with genotype 2 HCV infection, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
08 Jul 2017
Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
05 Oct 2019
The combination of sofosbuvir and velpatasvir is safe and effective for the treatment of hepatitis C virus (HCV) in patients with end-stage renal disease (ESRD) undergoing haemodialysis, a study has shown.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.